Search results
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
Clinical Trials Arena via Yahoo Finance· 2 weeks agoBristol Myers Squibb’s (BMS) blockbuster cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab)...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 3 days agoBristol Myers Squibb BMY announced that the FDA will now decide on the biologics license application...
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
Zacks via Yahoo Finance· 2 years agoBristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line...
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
Zacks via Yahoo Finance· 2 years agoExelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy...
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney...
Benzinga via Yahoo Finance· 4 months agoBristol Myers Squibb & Co (NYSE:BMY) announced that Opdivo (nivolumab) plus Yervoy (ipilimumab)...
Bristol Myers drug combo fails to meet main goal in kidney cancer trial
Reuters via Yahoo News· 2 years agoYervoy and top selling cancer drug Opdivo - is already approved in the United States as a first line...
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
Zacks via Yahoo Finance· 12 months agoBristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer...
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 8.8%...
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
Zacks via Yahoo Finance· 1 year agoIovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer...
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Zacks via Yahoo Finance· 5 months agoBristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its...